ライフサイエンスコーパス: thromboembolic

1 Adverse events of interest were thromboembolic adverse events (six [7%] patients receivi

2 be associated with increased risks of venous thromboembolic and arterial disease.

3 the incidence of first and recurrent venous thromboembolic and arterial events.

4 the rhythm-control group, P=0.61), including thromboembolic and bleeding events.

5 fection is associated with increased risk of thromboembolic and cardiovascular comorbid conditions.

6 ociated with a coagulopathy characterized by thromboembolic and hemorrhagic complications.

7 In vivo, in rats subjected to thromboembolic brain ischemia, we found that intraischem

8 ke that combines high age and tauopathy with thromboembolic cerebral ischemia.

9 The only thromboembolic complication was transient ischemic attac

10 as associated with a higher risk of death or thromboembolic complications and a higher risk of bleedi

11 as associated with a higher risk of death or thromboembolic complications and a higher risk of bleedi

12 Thromboembolic complications and new-onset atrial arrhyt

13 The impact of HALT on thromboembolic complications and structural valve degene

14 e environments in mediating life-threatening thromboembolic complications associated with shear-media

15 e Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARI

16 as a major pathologic event in COVID-19, and thromboembolic complications listed among life-threateni

17 athy that serves as the substrate for AF and thromboembolic complications might improve treatment out

18 In children, thromboembolic complications occur about 7 times less of

19 Thromboembolic complications occurred in 4 patients (0.3

20 is associated with better survival and lower thromboembolic complications than UH.

21 k between AF and brain injury extends beyond thromboembolic complications to include a cardiovasculop

22 The absolute risk of thromboembolic complications was higher among patients w

23 Periprocedural thromboembolic complications were assessed.

24 The treatment and prevention of thromboembolic complications will also be addressed.

25 cardiovascular (CV) sequelae, which include thromboembolic complications, cardiac, and vascular toxi

26 dent protective factor against mortality and thromboembolic complications, regardless of timing of pr

27 None of the patients had DCCV-related thromboembolic complications.

28 post-tonsillectomy bleeding and in potential thromboembolic complications.

29 nferior to fondaparinux in the prevention of thromboembolic complications.

30 Outcomes were death, disability, and thromboembolic complications.

31 hose at low risk of bleeding or high risk of thromboembolic complications.

32 n the pathogenesis of AF and its age-related thromboembolic complications.

33 ntravascular coagulation (DIC) and recording thromboembolic complications.

34 tion which if left untreated could result in thromboembolic complications.

35 Anticoagulation reduces thromboembolic complications; the newer anticoagulants h

36 Thromboembolic conditions are divided into arterial and

37 Thromboembolic conditions were estimated to account for

38 treating or preventing acute thrombotic and thromboembolic conditions.

39 onventional D-dimer cutoff level to rule out thromboembolic disease (< 500 ug/L).

40 The etiology of pediatric venous thromboembolic disease (VTE) is multifactorial, and in m

41 uring 2012, observed rates of stroke, venous thromboembolic disease (VTE), and heart failure were low

42 ing cardiovascular injury, including that of thromboembolic disease and arrhythmia, and to discuss th

43 sfunction is often observed in patients with thromboembolic disease and was previously shown to be as

44 further inform our emerging understanding of thromboembolic disease in COVID-19.

45 sfunction appear feasible and safe assessing thromboembolic disease in critically ill patients.

46 Thromboembolic disease is common in coronavirus disease-

47 Of 26 autopsies, 11 (42%) had thromboembolic disease not clinically suspected and 3 of

48 a prothrombotic state increases the risk of thromboembolic disease through the activation of coagula

49 Diagnosing thromboembolic disease typically includes D-dimer testin

50 Thromboembolic disease was contextualized by premortem A

51 anging from microvascular thrombosis, venous thromboembolic disease, and stroke.

52 iomyopathies, arrhythmias, valvular disease, thromboembolic disease, aortic disease, and cerebrovascu

53 This report summarizes evidence for thromboembolic disease, potential diagnostic and prevent

54 eft heart disease, lung disease, and chronic thromboembolic disease.

55 off-label clinical application in pediatric thromboembolic disease.

56 sease 2019 (COVID-19), linking pulmonary and thromboembolic disease.

57 sis, with 467 patients (3.5%) diagnosed with thromboembolic disease.

58 Autopsies revealed frequent thromboembolic disease.

59 ation, recurrent infections, and angiopathic thromboembolic disease; the disorder followed an autosom

60 Thromboembolic diseases such as myocardial infarction, s

61 e been found effective in treating different thromboembolic diseases.

62 Although arterial and venous thromboembolic disorders are among the most frequent cau

63 hibition may offer a safe strategy to combat thromboembolic disorders including ischemic stroke.

64 atients were included who accounted for 1858 thromboembolic emergencies (48 per month) during the 3-y

65 during the 3-year Baseline interval and 1077 thromboembolic emergencies (83 per month) during the 1-y

66 ade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common g

67 fter a median of 17 months, death or a first thromboembolic event (intention-to-treat analysis) had o

68 ositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]).

69 e aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638).

70 f TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a

71 f TTP-related death, recurrence of TTP, or a thromboembolic event during the trial treatment period;

72 There was one grade 3 thromboembolic event in the combination arm and one inte

73 A major thromboembolic event occurred in 1 patient (0.3%) in the

74 Thromboembolic event rates differed markedly in non-anti

75 We explored the variation in thromboembolic event rates in a non-anticoagulated AF po

76 cer patients were diagnosed with an arterial thromboembolic event vs 413 (0.11%) controls (odds ratio

77 diagnosis and seven of those had documented thromboembolic event while on extracorporeal membrane ox

78 low-up, 6 patients (4.4%) had a postreversal thromboembolic event, and 20 patients (14.6%) died.

79 lower risk of coronary heart disease, venous thromboembolic event, and cerebrovascular disease than i

80 liver toxicity, two respiratory failure, one thromboembolic event, and one sudden death).

81 ents (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficien

82 c electronic device implantation, infection, thromboembolic event, hemodialysis, and readmission).

83 -hospital mortality or complications (major: thromboembolic event, pneumonia, sepsis, stroke, or myoc

84 (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological e

85 lder age, smoking, node negativity, or prior thromboembolic event.

86 ascular event, and 14,550 had a first venous thromboembolic event.

87 anticoagulated patients experienced nonfatal thromboembolic events (1.1%/year), whereas 13 with apica

88 [<1%]), dyspnoea (nine [2%] vs 38 [7%]), and thromboembolic events (11 [2%] vs 26 [5%]).

89 years; 30 of the patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events)

90 readmissions, followed by cardiovascular or thromboembolic events (18%).

91 [2%] patients), and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than

92 Thromboembolic events (5 [7%] vs 4 [6%]) and mean (SD) c

93 Rates of thromboembolic events (6%) and hepatobiliary adverse eve

94 rhythmias (aOR: 12.4; 95% CI: 11.0 to 14.0), thromboembolic events (aOR: 2.4; 95% CI: 2.0 to 2.9), pr

95 vents, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myoca

96 and nonsignificant lower risk of stroke and thromboembolic events (odds ratio =0.61, 95% confidence

97 This study evaluated the incidence of thromboembolic events (TE) in post-LAAEI cases "on" and

98 Thrombotic/thromboembolic events (TEE) have been reported with plas

99 ied a boxed safety warning about the risk of thromboembolic events (TEEs), with TEEs reported in 0.5%

100 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events (ten [7%] vs 11 [8%]), lethargy (t

101 requirements without increasing the risk of thromboembolic events across a wide variety of liver tra

102 Here, we describe the vascular and thromboembolic events afflicting a series of 40 patients

103 the incidence of LAA thrombus formation and thromboembolic events after LAAI.

104 dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve i

105 factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve r

106 Regarding safety, neither thromboembolic events among mothers nor Tpo-RA-related f

107 The rate of thromboembolic events among patients with coronavirus di

108 The safety outcomes were thromboembolic events and all-cause mortality within 30

109 , patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those wit

110 orted in 29 of 113 participants (25.7%) with thromboembolic events and in 11 of 34 participants (32.4

111 Background Thromboembolic events and intraoperative rupture are the

112 Thromboembolic events and intraoperative rupture were re

113 optical density; had a higher prevalence of thromboembolic events and reached platelet count nadir l

114 Data regarding the risk of thromboembolic events and stroke after LAAI are sparse.

115 In the main trial, the risk of death or thromboembolic events and the risk of life-threatening,

116 ma samples obtained from patients with prior thromboembolic events are denser and less susceptible to

117 Prophylaxis against and treatment of thromboembolic events are necessary and should consider

118 of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less

119 morrhage or hydrocephalus upon follow-up CT, thromboembolic events before discharge, and the 3-month

120 In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before

121 imator was used to compare risks of arterial thromboembolic events between cancer and noncancer group

122 There were no differences in thromboembolic events between the groups (22 [6.0%] vs 3

123 nd raloxifene were associated with increased thromboembolic events compared with placebo; tamoxifen w

124 Thromboembolic events contribute greatly to morbidity an

125 than enoxaparin in the prevention of venous thromboembolic events during a period of immobilization

126 s population for prophylaxis or treatment of thromboembolic events for 64 years.

127 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

128 d Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

129 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who r

130 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, pat

131 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).

132 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201)

133 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201),

134 systematically identified symptomatic venous thromboembolic events in both trials.

135 Consequently, the prevention of thromboembolic events in LA positives might improve surv

136 b and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older

137 agents, addresses challenges with preventing thromboembolic events in patients at high risk and descr

138 egarding the effectiveness and occurrence of thromboembolic events in patients treated with prothromb

139 4-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointes

140 erapy is the standard therapy for preventing thromboembolic events in patients with atrial fibrillati

141 Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillati

142 E constituted 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillati

143 rophylactic anticoagulation and treatment of thromboembolic events in patients with hepatic insuffici

144 Postreversal thromboembolic events occurred in 10 (5%) patients at 30

145 Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in

146 Thromboembolic events occurred in 26 patients (7.0%) in

147 Thromboembolic events occurred in 4 subjects receiving d

148 Thromboembolic events occurred in one patient receiving

149 ring days 1-720, ten (1.2% per patient year) thromboembolic events occurred in the Fiix-PT group vers

150 e death, one nonfatal stroke, and two venous thromboembolic events occurred in the upadacitinib group

151 Three thromboembolic events occurred within 3 days (one in the

152 es or major adverse cardiac events including thromboembolic events occurred.

153 Thromboembolic events on dabigatran led to early termina

154 ct of bariatric surgery on long-term risk of thromboembolic events outline a significant reduction in

155 Thromboembolic events secondary to rupture or erosion of

156 Emergency visits for thromboembolic events spanning 1-4 years before treatmen

157 ial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infa

158 The high incidence of thromboembolic events suggests an important role of COVI

159 i-Platelet Trialists' Collaboration arterial thromboembolic events through W96.

160 ially be used to predict the risk of diverse thromboembolic events under physiological and pathologic

161 et Trialists' Collaboration-defined arterial thromboembolic events was 1.9%, 0.9%, 1.1%, 2.1%, and 1.

162 The number of patients with venous thromboembolic events was 158 (4.0%) of 3958 with availa

163 A lower incidence of combined thromboembolic events was also observed with antiplatele

164 f hospitalizations for bleeding and arterial thromboembolic events were estimated in an intent-to-tre

165 Factors associated with thromboembolic events were female sex (odds ratio [OR],

166 Risk factors for thromboembolic events were female sex and middle cerebra

167 nosis, the interval 30-day risks of arterial thromboembolic events were higher in cancer patients vs

168 Thromboembolic events were lower in the ruxolitinib grou

169 neurysm coiling or balloon-assisted coiling, thromboembolic events were more frequent than were intra

170 events and 33 and 58 and 12 and 28 arterial thromboembolic events were observed during follow-up, re

171 No thromboembolic events were observed during the study.

172 nosis, the 30-day interval risks of arterial thromboembolic events were similar between cancer patien

173 raventricular hemorrhage, hydrocephalus, and thromboembolic events were similar between groups.

174 hagic and ischemic stroke, or between venous thromboembolic events with or without pulmonary embolism

175 sulted in a 28% reduction in fatal and major thromboembolic events without a significant increase in

176 risk of venous and arterial fatal and major thromboembolic events without significantly increasing m

177 ricular arrhythmias, 5 cardiac deaths, and 5 thromboembolic events).

178 A total of 71 thromboembolic events, 32 systemic and 39 venous, occurr

179 site endpoint of HIT-specific complications (thromboembolic events, amputation, skin necrosis) occurr

180 very, persistent heart failure, arrhythmias, thromboembolic events, and death.

181 as not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control gr

182 ment-related deaths, second primary cancers, thromboembolic events, and peripheral neuropathy.

183 heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention).

184 im of this study was to compare the risk for thromboembolic events, bleeding, and mortality associate

185 collect prospective multicenter outcomes of thromboembolic events, bleeding, and mortality for patie

186 arboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative compl

187 hospitalization, but no increase in risks of thromboembolic events, bleeding-related hospitalization,

188 d thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between

189 ble electronic devices and increased risk of thromboembolic events, clinical intervention for device-

190 UC]); incidence of breast cancer, fractures, thromboembolic events, coronary heart disease events, st

191 agnosis codes were used to identify arterial thromboembolic events, defined as a composite of myocard

192 ic events outline a significant reduction in thromboembolic events, driven by a reduction in deep vei

193 here show that systemic hypoxia accelerates thromboembolic events, functionally stimulated by the ac

194 ll as 2-year risk of death, hospitalization, thromboembolic events, heart failure (HF), and AF progre

195 Outcome was a composite of thromboembolic events, heart failure hospitalizations, v

196 levant safety end points, including arterial thromboembolic events, MI, stroke or transient ischemic

197 nfections, herpes zoster, malignancy, venous thromboembolic events, or deaths were reported; one seri

198 first 24 hours and incidence of rebleeding, thromboembolic events, or mortality.

199 No thrombotic or thromboembolic events, systemic allergic reactions (incl

200 Secondary outcomes were the number of major thromboembolic events, the number of days free from coma

201 ving oral anticoagulation, bleeding, but not thromboembolic events, was increased in patients with li

202 center, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibril

203 sease, especially by increasing the risk for thromboembolic events.

204 pathogenesis of atherosclerosis, leading to thromboembolic events.

205 safety parameters, including no evidence of thromboembolic events.

206 at high risk for arrhythmic sudden death and thromboembolic events.

207 ves during pregnancy is essential to prevent thromboembolic events.

208 carotid artery stenting reduces the rate of thromboembolic events.

209 s, non-O blood groups explain >30% of venous thromboembolic events.

210 higher incidence of both venous and arterial thromboembolic events.

211 ted, including all-cause mortality and fatal thromboembolic events.

212 associated complications of arrhythmias and thromboembolic events.

213 bleeding risk without a favorable effect on thromboembolic events.

214 ular atrial fibrillation is a major cause of thromboembolic events.

215 ia who present with atypical vascular and/or thromboembolic events.

216 cal patients are at risk for fatal and major thromboembolic events.

217 ficacy outcome was the composite of death or thromboembolic events.

218 age, incidence of seizures, and incidence of thromboembolic events.

219 osinophils may be required for prevention of thromboembolic events.

220 ined (HR: 0.34 vs. LT; 95% CI: 0.13 to 0.91) thromboembolic events.

221 Thirty-one percent had thromboembolic events; thromboelastography parameters di

222 of AC with in-hospital outcomes and describe thromboembolic findings on autopsies.

223 0.88; 95% confidence interval, 0.64-1.21) or thromboembolic (hazard ratio, 1.10; 95% confidence inter

224 latform for further study of a translational thromboembolic model of acute ischemic stroke.

225 patients (50 men and 50 women) with positive thromboembolic multiple detector computed tomography of

226 are characterized by rapid onset of multiple thromboembolic occlusions affecting diverse vascular bed

227 Patients were at high risk for thromboembolic or bleeding events (prior stroke/TIA 29%;

228 risk of death and hospitalizations, but not thromboembolic or bleeding events.

229 he prevention and treatment of microvascular thromboembolic pathologies, which are inaccessible to in

230 Chronic thromboembolic PH (CTEPH) is an important complication a

231 pulmonary arterial hypertension and chronic thromboembolic PH, explore the correlation between fibro

232 pulmonary arterial hypertension and chronic thromboembolic PH, the RV is exposed to a ~5 times incre

233 pulmonary arterial hypertension and chronic thromboembolic PH: as part of an adaptive response to pr

234 tic balloon pump being in situ, and possible thromboembolic phenomena.

235 following the established practice of using thromboembolic prophylaxis for critically ill hospitaliz

236 stance indicated severe or nonsevere chronic thromboembolic pulmonary hypertension (> 900 or </= 900

237 en applied to patients with residual chronic thromboembolic pulmonary hypertension (CTEPH) after pulm

238 The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmon

239 Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare,

240 Chronic thromboembolic pulmonary hypertension (CTEPH) is charact

241 Chronic thromboembolic pulmonary hypertension (CTEPH) is the res

242 Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) that is no

243 els was assessed in 34 patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing

244 Chronic thromboembolic pulmonary hypertension (CTEPH) was confir

245 g of the pathophysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be ac

246 hould have clinical surveillance for chronic thromboembolic pulmonary hypertension (CTEPH), with vent

247 Patients with severe chronic thromboembolic pulmonary hypertension (n = 15) had highe

248 patients at higher risk of dying of chronic thromboembolic pulmonary hypertension and identifies a l

249 Chronic thromboembolic pulmonary hypertension results from incom

250 mall-vessel disease in patients with chronic thromboembolic pulmonary hypertension undergoing PEA to

251 ard-approved study, 20 patients with chronic thromboembolic pulmonary hypertension were examined at 1

252 of 679 patients newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively

253 ry arterial hypertension and 26 with chronic thromboembolic pulmonary hypertension) and compared them

254 utable to right ventricular failure (chronic thromboembolic pulmonary hypertension).

255 Chronic thromboembolic pulmonary hypertension, a rare complicati

256 are pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary hyp

257 patients who are inoperable and have chronic thromboembolic pulmonary hypertension, riociguat, a stim

258 For patients with chronic thromboembolic pulmonary hypertension, surgical pulmonar

259 studied for possible development of chronic thromboembolic pulmonary hypertension.

260 tion of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

261 with severe compared with nonsevere chronic thromboembolic pulmonary hypertension.

262 d postoperative outcome after PEA in chronic thromboembolic pulmonary hypertension.

263 ean age, 57 years) underwent PEA for chronic thromboembolic pulmonary hypertension.

264 d and not-operated patients who have chronic thromboembolic pulmonary hypertension.

265 up to 4% of patients with PE develop chronic thromboembolic pulmonary hypertension.

266 treatment for patients with operable chronic thromboembolic pulmonary hypertension.

267 24 mo, suggesting they could develop chronic thromboembolic pulmonary hypertension.

268 both conditions results in a higher risk for thromboembolic-related adverse events but a paradoxical

269 ound disruption, cardiac/transfusion, venous thromboembolic, renal, and neurological complications, a

270 outpatients with AF and intermediate to high thromboembolic risk (CHADS2 score >/=2 and CHA2DS2-VASc

271 Thromboembolic risk across surgical techniques was asses

272 an was independently associated with a lower thromboembolic risk after controlling for time-varying e

273 not exclusively, to the overall increase of thromboembolic risk in AF.

274 sts (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been in

275 role of insulin versus no insulin therapy on thromboembolic risk in patients with diabetes and AF.

276 of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

277 of Rivaroxaban [JNJ-39039039] on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients)

278 Although thromboembolic risk is currently defined by clinical sco

279 2-VASc score instead of the CHADS2 score for thromboembolic risk stratification and initiation of ora

280 We highlight the increased thromboembolic risk with coexisting AF and type 2 diabet

281 ex category) score, incompletely account for thromboembolic risk, and emerging evidence suggests that

282 For transgender women, CSHT has known thromboembolic risk, and lower-dose transdermal estrogen

283 important variable in the stratification of thromboembolic risk, particularly in patients with nonva

284 D and aortic valve stenosis but may increase thromboembolic risk.

285 requiring insulin did not imply an increased thromboembolic risk.

286 loss of LAA mechanical function may increase thromboembolic risk.

287 ostic tools offer insight into AF burden and thromboembolic risk.

288 uate the effect of type of Fontan surgery on thromboembolic risk.

289 ble effectiveness and concerns regarding its thromboembolic risks.

290 udy sample coming from our GWAS on pediatric thromboembolic stroke (combined P = 7.88 x 10(-7)).

291 Following thromboembolic stroke bexarotene enhanced autophagy in t

292 deaths due to hemorrhagic complications and thromboembolic stroke in clinics worldwide.

293 Thus, in a new large-vessel thromboembolic stroke model in mice, this cotreatment si

294 traumatic brain injury, postcraniotomy, and thromboembolic stroke patients, whereas gabapentin/prega

295 ation, whereas the MAX(DTE) animal sustained thromboembolic strokes.

296 progression-free survival (PFS; overall) and thromboembolic (TE) event rate.

297 H20 combination arm as a result of increased thromboembolic (TE) events.

298 rrelation between D-dimer levels in positive thromboembolic thoracic computed tomography (CT) with th

299 he incidences of HIT-specific complications (thromboembolic venous/arterial events, amputations, recu

300 are at high risk for life-threatening venous thromboembolic (VTE) events.